Anti-VEGF treatments are the best available treatment for wet age-related macular degeneration (AMD). Learn how these injection medications can maintain and even improve vision in AMD patients.
/PRNewswire/ The vascular endothelial growth factor (VEGF) inhibitors market is anticipated to grow by USD 10.40 billion, progressing at a CAGR of 7.76%.
For treatment of retinopathy of prematurity, intravitreal aflibercept (Eylea) and laser photocoagulation showed equivocal results at age 2 years, a European-based clinical trial found.
DelveInsight s, Glaucoma Pipeline Insight 2023 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Glaucoma pipeline landscape. It covers the Glaucoma pipeline.
The global Diabetic Macular Edema Market Size is expected to reach a valuation of US$ 3.7 Billion by the end of 2022, and further expand at a CAGR of 1.2% from 2022 to 2032. The market is projected to reach a valuation of ~US$ 4.2 Billion by the end of 2032.An Uptake of Intravitreal Implants by Patients to Drive Gro.